cbdMD, Inc. (YCBD)
| Market Cap | 7.56M -12.1% |
| Revenue (ttm) | 19.98M +2.0% |
| Net Income | -3.11M |
| EPS | -0.36 |
| Shares Out | 10.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,669 |
| Open | 0.6716 |
| Previous Close | 0.6870 |
| Day's Range | 0.6700 - 0.7200 |
| 52-Week Range | 0.4701 - 2.5600 |
| Beta | 2.13 |
| Analysts | Buy |
| Price Target | 2.00 (+177.78%) |
| Earnings Date | May 14, 2026 |
About YCBD
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and he... [Read more]
Financial Performance
In fiscal year 2025, cbdMD's revenue was $19.19 million, a decrease of -1.50% compared to the previous year's $19.48 million. Losses were -$4.38 million, -43.21% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for YCBD stock is "Buy" and the 12-month stock price target is $2.0.
News
cbdMD appoints Wade Brown as Chief Marketing Officer
cbdMD (YCBD) announced the appointment of Wade Brown as Chief Marketing Officer. “Brown joined cbdMD in March 2025 and has been central to stabilizing the Company’s brand portfolio and supporting…
cbdMD Appoints Wade Brown Chief Marketing Officer
Veteran consumer-wellness growth operator to lead multi-brand expansion across DTC, Amazon, retail, and new categories CHARLOTTE, N.C., June 16, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD),...
cbdMD Earnings Call Transcript: Q2 2026
Net sales rose 19% year-over-year to $5.6 million, driven by core growth and the Bluebird Botanicals acquisition. Gross margin declined to 58% due to wholesale mix and compliance costs, while strategic investments in Medicare and regulatory agility position the company for long-term growth.
cbdMD Quarterly report: Q2 2026
cbdMD has published its Q2 2026 quarterly earnings report on May 14, 2026.
cbdMD Earnings release: Q2 2026
cbdMD released its Q2 2026 earnings on May 14, 2026, summarizing the period's financial results.
cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
CHARLOTTE, N.C. , May 14, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD...
cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results
CHARLOTTE, N.C., May 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a co...
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based ca...
cbdMD Transcript: AGM 2026
The meeting saw all director nominees elected and all proposals, including a reverse stock split, preferred stock issuances, and the 2025 Equity Compensation Plan, approved by strong majorities. Voting was conducted online, and results will be filed with the SEC.
cbdMD Registration statement: Registration Filing
cbdMD filed a registration statement on February 20, 2026, providing details about a securities offering with the SEC.
cbdMD Earnings Call Transcript: Q1 2026
Sequential revenue growth continued with Q1 FY26 up 12% from Q4, driven by D2C and wholesale channels. Gross margin declined to 60% due to mix shift, but net loss improved significantly. Acquisition of Bluebird Botanicals and strengthened liquidity position support future growth.
cbdMD Earnings release: Q1 2026
cbdMD released its Q1 2026 earnings on February 17, 2026, summarizing the period's financial results.
cbdMD Quarterly report: Q1 2026
cbdMD has published its Q1 2026 quarterly earnings report on February 17, 2026.
cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026
CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD bran...
cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results
CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a c...
cbdMD Proxy statement: Proxy Filing
cbdMD filed a proxy statement on February 12, 2026, providing details for shareholder voting and corporate governance matters.
cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum
CHARLOTTE, N.C., Feb. 2, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in wellness and hemp-derived consumer products, today announced a major distribution expansion for ...
cbdMD Proxy statement: Proxy Filing
cbdMD filed a proxy statement on February 2, 2026, providing details for shareholder voting and corporate governance matters.
cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways
CHARLOTTE, N.C., Jan. 29, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, today announced a strategic initiative to integrate and expand ...
cbdMD Registration statement: Registration Filing
cbdMD filed a registration statement on January 22, 2026, providing details about a securities offering with the SEC.
cbdMD Announces Strategic Acquisition of Bluebird Botanicals
CHARLOTTE, N.C., Jan. 14, 2026 /PRNewswire/ -- cbdMD, Inc (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, announced today the closing of the acquisition of substantially ...
cbdMD Registration statement: Registration Filing
cbdMD filed a registration statement on January 5, 2026, providing details about a securities offering with the SEC.
cbdMD Registration statement: Registration Filing
cbdMD filed a registration statement on December 22, 2025, providing details about a securities offering with the SEC.
cbdMD Earnings Call Transcript: Q4 2025
Fiscal 2025 saw improved operating results, stronger balance sheet, and margin gains, with Oasis beverage expansion and regulatory shifts offering growth potential. Regulatory changes, including a White House executive order, may drive significant new demand in 2026.
cbdMD Annual report: Q4 2025
cbdMD has published its Q4 2025 annual report on December 19, 2025.